A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of David Camidge,  MD, PhD

David Camidge, MD, PhD

Study ID

Protocol Number: 18-0685

More information available at ClinicalTrials.gov: NCT03504488

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers